Skip to main content
SpringerLink
Log in

How Much Isolation Is Enough for Allografts?

  • Chapter
  • First Online:
Allogeneic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1423 Accesses

Abstract

Since the beginning of allogeneic transplant procedures, isolation precautions have been used in an effort to prevent infectious complications. However, the medical benefit has been increasingly questioned and, given the substantial costs associated with each measure, practices have been subject to institutional variability. Recent examples from our own institution range from determining the needs for and planning the construction of a new clinical facility, to halting the spread of vancomycin-resistant Enterococcus (VRE), understanding the source of a parainfluenza outbreak, and analyzing the potential for delays in response time to acute emergencies while putting on contact isolation materials (gowns, masks, gloves, etc.). Standards for isolation may be subject to change when managing infection outbreaks or with new construction, and may be influenced by the changing financial pressures of the institution.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 49:1-125 CE121-127

    Google Scholar 

  2. Hagen EA, Stern H, Porter D et al (2003) High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 36:9-15

    Article  PubMed  Google Scholar 

  3. Busca A, Lovisone E, Aliberti S et al (2003) Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 8:303-311

    Article  PubMed  CAS  Google Scholar 

  4. Junghanss C, Marr KA, Carter RA et al (2002) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol Blood Marrow Transplant 8:512-520

    Article  PubMed  Google Scholar 

  5. Junghanss C, Boeckh M, Carter RA et al (2002) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99:1978-1985

    Article  PubMed  CAS  Google Scholar 

  6. McNeil MM, Nash SL, Hajjeh RA et al (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33:641-647

    Article  PubMed  CAS  Google Scholar 

  7. van Burik JH, Leisenring W, Myerson D et al (1998) The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 77:246-254

    Article  Google Scholar 

  8. Marr KA, Seidel K, White TC, Bowden RA (2000) Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181:309-316

    Article  PubMed  CAS  Google Scholar 

  9. Fukuda T, Boeckh M, Carter RA et al (2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102:827-833

    Article  PubMed  CAS  Google Scholar 

  10. McCann S, Byrne JL, Rovira M et al (2004) Outbreaks of infectious diseases in stem cell transplant units: A silent cause of death for patients and transplant programmes. Bone Marrow Transplant 33:519-529

    Article  PubMed  CAS  Google Scholar 

  11. Sherertz RJ, Belani A, Kramer BS et al (1987) Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 83:709-718

    Article  PubMed  CAS  Google Scholar 

  12. Anaissie EJ, Costa SF (2001) Nosocomial aspergillosis is waterborne. Clin Infect Dis 33:1546-1548

    Article  PubMed  CAS  Google Scholar 

  13. Cornet M, Levy V, Fleury L et al (1999) Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 20:508-513

    Article  PubMed  CAS  Google Scholar 

  14. Wald A, Leisenring W, van Burik JA, Bowden RA (1997) Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175:1459-1466

    Article  PubMed  CAS  Google Scholar 

  15. Orth B, Frei R, Itin PH et al (1996) Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med 125:799-806

    PubMed  CAS  Google Scholar 

  16. Lyytikainen O, Golovanova V, Kolho E et al (2001) Outbreak caused by tobramycin-resistant Pseudomonas aeruginosa in a bone marrow transplantation unit. Scand J Infect Dis 33:445-449

    Article  PubMed  CAS  Google Scholar 

  17. Oren I, Zuckerman T, Avivi I et al (2002) Nosocomial outbreak of Legionella pneumophila serogroup 3 pneumonia in a new bone marrow transplant unit: Evaluation, treatment and control. Bone Marrow Transplant 30:175-179

    Article  PubMed  CAS  Google Scholar 

  18. Ljungman P (2001) Respiratory virus infections in stem cell transplant patients: The European experience. Biol Blood Marrow Transplant Suppl 7:5S-7S

    Article  Google Scholar 

  19. Champlin RE, Whimbey E (2001) Community respiratory virus infections in bone marrow transplant recipients: The M.D. Anderson Cancer Center experience. Biol Blood Marrow Transplant Suppl 7:8S-10S

    Article  Google Scholar 

  20. Nichols WG, Gooley T, Boeckh M (2001) Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: The Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant Suppl 7:11S-15S

    Article  Google Scholar 

  21. Harrington RD, Hooton TM, Hackman RC et al (1992) An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 165:987-993

    Article  PubMed  CAS  Google Scholar 

  22. Whimbey E, Champlin RE, Englund JA et al (1995) Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 16:393-399

    PubMed  CAS  Google Scholar 

  23. Taylor GS, Vipond IB, Caul EO (2001) Molecular epidemiology of outbreak of respiratory syncytial virus within bone marrow transplantation unit. J Clin Microbiol 39:801-803

    Article  PubMed  CAS  Google Scholar 

  24. Recommendations for preventing the spread of vancomycin resistance (1995) Recommendations of the hospital infection control practices advisory committee (HICPAC). MMWR Recomm Rep 44:1-13

    Google Scholar 

  25. Uttley AH, Collins CH, Naidoo J, George RC (1988) Vancomycin-resistant enterococci. Lancet 1:57-58

    Article  PubMed  CAS  Google Scholar 

  26. Kirkpatrick BD, Harrington SM, Smith D et al (1999) An outbreak of vancomycin-dependent Enterococcus faecium in a bone marrow transplant unit. Clin Infect Dis 29:1268-1273

    Article  PubMed  CAS  Google Scholar 

  27. Weinstock DM, Conlon M, Iovino C et al (2007) Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13:615-621

    Article  PubMed  Google Scholar 

  28. Aker SN, Cheney CL (1983) The use of sterile and low microbial diets in ultraisolation environments. JPEN J Parenter Enteral Nutr 7:390-397

    Article  PubMed  CAS  Google Scholar 

  29. Bodey GP, Freireich EJ, Frei E III (1969) Studies of patients in a laminar air flow unit. Cancer 24:972-980

    Article  PubMed  CAS  Google Scholar 

  30. Bodey GP, Gehan EA, Freireich EJ, Frei E III (1971) Protected environment-prophylactic antibiotic program in the chemotherapy of acute leukemia. Am J Med Sci 262:138-151

    Article  PubMed  CAS  Google Scholar 

  31. Dietrich M, Gaus W, Vossen J et al (1977) Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. A prospective cooperative study of gnotobiotic care in acute leukemia patients. I: Clinical results. Infection 5:107-114

    Article  PubMed  CAS  Google Scholar 

  32. Klastersky J, Debusscher L, Weerts D, Daneau D (1974) Use of oral antibiotics in protected units environment: Clinical effectiveness and role in the emergence of antibiotic-resistant strains. Pathol Biol (Paris) 22:5-12

    CAS  Google Scholar 

  33. Levine AS, Siegel SE, Schreiber AD et al (1973) Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 288:477-483

    Article  PubMed  CAS  Google Scholar 

  34. Ribas-Mundo M, Granena A, Rozman C (1981) Evaluation of a protective environment in the management of granulocytopenic patients: A comparative study. Cancer 48:419-424

    Article  PubMed  CAS  Google Scholar 

  35. Schimpff SC, Greene WH, Young VM et al (1975) Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 82:351-358

    PubMed  CAS  Google Scholar 

  36. Schwartz SA, Perry S (1966) Patient protection in cancer chemotherapy. JAMA 197:623-627

    Article  PubMed  CAS  Google Scholar 

  37. Yates JW, Holland JF (1973) A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 32:1490-1498

    Article  PubMed  CAS  Google Scholar 

  38. Rodriguez V, Bodey GP, Freireich EJ et al (1978) Randomized trial of protected environment-prophylactic antibiotics in 145 adults with acute leukemia. Medicine (Baltimore) 57:253-266

    CAS  Google Scholar 

  39. Buckner CD, Clift RA, Sanders JE et al (1978) Protective environment for marrow transplant recipients: A prospective study. Ann Intern Med 89:893-901

    PubMed  CAS  Google Scholar 

  40. Storb R, Prentice RL, Buckner CD et al (1983) Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 308:302-307

    Article  PubMed  CAS  Google Scholar 

  41. Beelen DW, Elmaagacli A, Muller KD et al (1999) Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: Final results and long-term follow-up of an open-label prospective randomized trial. Blood 93:3267-3275

    PubMed  CAS  Google Scholar 

  42. Passweg JR, Rowlings PA, Atkinson KA et al (1998) Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 21:1231-1238

    Article  PubMed  CAS  Google Scholar 

  43. Yokoe DS, Mermel LA, Anderson DJ et al (2008) A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol 29:S12-21

    Article  PubMed  Google Scholar 

  44. Boyce JM, Pittet D (2002) Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 51:1-45 quiz CE41-44

    PubMed  Google Scholar 

  45. Pittet D, Simon A, Hugonnet S et al (2004) Hand hygiene among physicians: Performance, beliefs, and perceptions. Ann Intern Med 141:1-8

    PubMed  Google Scholar 

  46. Smith GC, Pell JP (2003) Parachute use to prevent death and major trauma related to gravitational challenge: Systematic review of randomised controlled trials. BMJ 327:1459-1461

    Article  PubMed  Google Scholar 

  47. (1994) Guideline for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. Respir Care 39:1191-1236

    Google Scholar 

  48. Garner JS (1996) Guideline for isolation precautions in hospitals. The hospital infection control practices advisory committee. Infect Control Hosp Epidemiol 17:53-80

    Article  PubMed  CAS  Google Scholar 

  49. Larson EL (1995) APIC guideline for handwashing and hand antisepsis in healthcare settings. Am J Infect Control 23:251-269

    Article  PubMed  CAS  Google Scholar 

  50. Giles FJ, Rodriguez R, Weisdorf D et al (2004) A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 28:559-565

    Article  PubMed  CAS  Google Scholar 

  51. Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590-2598

    Article  PubMed  CAS  Google Scholar 

  52. Ketterer N, Zaman K, Luthi F et al (2004) Conventional hospital room is as safe as sterile unit for high-dose chemotherapy and peripheral blood stem cells (PBSC) transplantation. Blood 104:390b abstract 5222

    Article  Google Scholar 

  53. Cantoni R, Passweg J, Weisser M et al (2004) Abandoning care in laminar air flow (LAF) units and routine high dose intravenous immunoglobulines (IVIG) in allogeneic hematopoietic stem cell transplantation (HSCT) does not increase mortality and rate of infections. Blood 104:351b abstract 5072

    Google Scholar 

  54. Agha ME, Yeager AM, Evans C et al (2004) Outpatient high-dose chemotherapy and autologous hematopoietic stem cell transplantation for multiple myeloma is associated with a low infection safety profile. Blood 104:351b abstract 5070

    Google Scholar 

  55. Halim TY, Lavoie JC, Barnett MJ et al (2004) High risk AML outpatient management: A retrospective analysis of bacteremia incidence following chemotherapy. Blood 104:252a abstract 884

    Google Scholar 

  56. Sasaki T, Akaho R, Sakamaki H et al (2000) Mental disturbances during isolation in bone marrow transplant patients with leukemia. Bone Marrow Transplant 25:315-318

    Article  PubMed  CAS  Google Scholar 

  57. Cohen MZ, Ley C, Tarzian AJ (2001) Isolation in blood and marrow transplantation. West J Nurs Res 23:592-609

    PubMed  CAS  Google Scholar 

  58. Gaskill D, Henderson A, Fraser M (1997) Exploring the everyday world of the patient in isolation. Oncol Nurs Forum 24:695-700

    PubMed  CAS  Google Scholar 

  59. Mank A, van der Lelie H (2003) Is there still an indication for nursing patients with prolonged neutropenia in protective isolation? An evidence-based nursing and medical study of 4 years experience for nursing patients with neutropenia without isolation. Eur J Oncol Nurs 7:17-23

    Article  PubMed  Google Scholar 

  60. Russell JA, Poon MC, Jones AR et al (1992) Allogeneic bone-marrow transplantation without protective isolation in adults with malignant disease. Lancet 339:38-40

    Article  PubMed  CAS  Google Scholar 

  61. Russell JA, Chaudhry A, Booth K et al (2000) Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: A 10-year experience. Biol Blood Marrow Transplant 6:109-114

    Article  PubMed  CAS  Google Scholar 

  62. Svahn BM, Remberger M, Myrback KE et al (2002) Homecare during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 100:4317-4324

    Article  PubMed  CAS  Google Scholar 

  63. van Tiel FH, Harbers MM, Kessels AG, Schouten HC (2005) Homecare versus hospital care of patients with hematological malignancies and chemotherapy-induced cytopenia. Ann Oncol 16:195-205

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Hematologic Malignancies, OHSU Cancer Institute, Oregon Health and Science University, Portland, OR, USA

    Brandon Hayes-Lattin

Authors
  1. Brandon Hayes-Lattin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospitals Case Medical Center, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hayes-Lattin, B. (2010). How Much Isolation Is Enough for Allografts?. In: Lazarus, H.M., Laughlin, M.J. (eds) Allogeneic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-478-0_40

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-478-0_40

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-33-6

  • Online ISBN: 978-1-59745-478-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation